In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only been possible with the use of high-dose therapy plus autologous stem cell transplantation. Novel agents are changing the treatment landscape, with combinations of daratumumab, dexamethasone, thalidomide, bortezomib and lenalidomide increasing the rates of complete remission and partial response compared to VAD.

In this podcast, the endless possible combinations are discussed by Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France. Speaking from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Prof. Mohty gives us his insight into induction therapy and also where we may be going next.